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1. Introduction
Bovine respiratory syncytial virus (BRSV), an economi-
cally important respiratory pathogen in calves, is a pri-
mary cause of lower respiratory tract disease, and is an 
etiologic component of the bovine respiratory disease 
complex. Several BRSV vaccines are commercially avail-
able; however, protection is incomplete following vac-
cination or natural infection, as re-infections are com-
mon [1]. BRSV is closely related to human respiratory 
syncytial virus (HRSV), yet is antigenically distinct. The 
attachment (G) glycoprotein of BRSV, which facilitates 
viral attachment to the host cell, is a major protective an-
tigen, capable of inducing virus-neutralizing (VN) anti-
bodies [2 and 3]. Two forms of BRSV G are synthesized, 
based on initiation at one of two methionyl codons: a 
full-length, type II integral membrane protein and a trun-
cated form which undergoes proteolytic cleavage and is 
secreted [4]. The BRSV G ectodomain, heavily glycosyl-
ated with O-linked sugars, is characteristically similar to 
mucins, which are host glycoproteins found in protec-
tive barriers. As a result, the glycosylation of the BRSV G 
protein may protect the viral protein from being recog-
nized as a foreign antigen [5]. Within the mucin-like ect-
odomain of BRSV G exists a region spanning amino ac-
ids 166–186, that was fully-conserved among nine BRSV 
isolates studied [6]. This conserved region contains four 
cysteine residues, which are disulfide-linked, forming a 
characteristic “cysteine noose” that may serve to stabi-
lize the area and be critical for receptor binding [7]. Bas-
tien et al. , identified a synthetic peptide corresponding 
to this conserved region that was able to induce signifi-
cant BRSV-specific antibodies in calves and was capable 
of preventing BRSV-associated pneumonia in the natu-
ral host [8].
Much of what is known regarding host responses to 
the G glycoprotein stems from the formalin-inactivated 
(FI)-RSV vaccine trials that not only failed to elicit pro-
tection, but also led to an exacerbated disease in vacci-
nated children, following natural exposure [9, 10]. The 
vaccine-enhanced disease associated with FI-RSV was 
the result of an imbalanced T helper 2 (Th2) immune re-
sponse, specifically attributed to the G glycoprotein [11–
18]. This biased response may be due to the failure of the 
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Abstract
Bovine respiratory syncytial virus (BRSV) is a primary cause of lower respiratory tract disease in calves. Protection is incomplete 
following vaccination or natural infection, as re-infections are common. The objectives of this study were to create plasmid DNA 
constructs encoding the full-length, secreted, or conserved region of the BRSV G glycoprotein, and to compare and evaluate their 
expression in cell culture and potential to induce antibody responses in BALB/c mice. Transfection of COS-7 cells with plasmid 
DNA resulted in expression of the BRSV G region from each of the plasmid DNA constructs. Following inoculation of BALB/c mice 
with plasmid DNA, a significant and equivalent anti-BRSV G IgG response was elicited to the full-length and truncated BRSV G 
proteins. These constructs may be used to study host pathological and immunological responses.
Keywords: Bovine respiratory syncytial virus, DNA vaccine, Attachment glycoprotein
3762
f u l l-l e n g t h a n d t r u n c a t e d BrSV g p r o t e i n S a n d a n t i B o d y r e S p o n S e S  i n m i c e   3763
G protein to evoke a cytotoxic T lymphocyte (CTL) re-
sponse. Moreover, the secreted form of the BRSV G pro-
tein has also been linked to a Th2-biased immune re-
sponse [19–21].
A number of approaches have been implemented to 
circumvent the shortcomings associated with the FI-
RSV vaccine. In particular, DNA vaccination is a novel 
method for eliciting an antigen-specific immune re-
sponse. DNA vaccination is advantageous in that plas-
mid DNA vaccines can be readily developed within the 
laboratory. Also, DNA vaccines can induce lasting im-
munity and have the capability of redirecting the pattern 
of the immune response [22].
Immunization of mice with plasmid DNA encoding 
the HRSV F protein induced virus-neutralizing antibod-
ies, CTLs, high levels of interferon-γ (IFN-γ), and protec-
tion against infection following viral challenge [23, 24]. 
Moreover, immunization of mice with plasmid DNA en-
coding full-length or secreted HRSV G resulted in a bal-
anced Th1/Th2 response following virus challenge, sim-
ilar to that observed during a natural infection [25, 26]. 
DNA encoding HRSV G induced virus-neutralizing an-
tibodies, substantial IFN-γ, lower yields of interleukin-
4 (IL-4) and IL-5, an absence of lung lesions when com-
pared to FI-RSV immunization, and protection against 
viral replication. Even when the immune response was 
biased towards a Th2-like pattern, by co-administration 
of DNA-IL-4 with DNA-G, there was still a reduction in 
viral titers, and an absence of lung eosinophilia follow-
ing virus challenge [27].
Earlier studies demonstrated the ability of plasmid 
DNA encoding BRSV G to elicit a significant BRSV G-
specific antibody response in calves [28]; however, these 
studies did not compare the ability of secreted or con-
served BRSV G to evoke an antibody response. The ob-
jectives of this study were to create plasmid DNA con-
structs encoding the full-length, secreted, or conserved 
region of the BRSV G glycoprotein, and to compare and 
evaluate their expression in cell culture and their ability 
to induce antibody responses in BALB/c mice. In this pa-
per, we report the ability of these plasmid constructs to 
be expressed in cell culture and to elicit a significant and 
equivalent anti-BRSV G IgG response in BALB/c mice.
2. Materials and methods
2.1. Cells and viruses
Bovine turbinate (BT) cells (National Veterinary Services 
Laboratory, Ames, IA) were grown in Dulbecco’s Mod-
ified Eagle Medium (DMEM) supplemented with 10% 
equine serum (HyClone, Logan, UT), and maintained 
in a 37 °C humidified chamber with 5% CO2. Confluent 
monolayers were infected with plaque-purified BRSV 
strain 375 at a multiplicity of infection (m.o.i.) of 0.01 in 
tissue culture flasks, and maintained at 33 °C in a humid-
ified chamber with 5% CO2 ( 2 weeks) until the cells 
demonstrated 50% cytopathic effect (CPE). The flasks 
were then frozen at −80 °C, thawed, aliquoted, then fro-
zen again at −80 °C until used.
2.2. Construction of plasmid DNA vector encoding the full-
length BRSV G glycoprotein
BRSV 375 was propagated in BT cells and RNA was ex-
tracted according to manufacturer’s instructions us-
ing TRIZOL LS reagent (Invitrogen, Carlsbad, CA). 
The 794 bp BRSV G glycoprotein cDNA sequence was 
generated from total RNA using Superscript II reverse 
transcriptase (Invitrogen) and the primer G2, 5′-GGT-
GGGATCCTAGATCTGTGTAGTTGATTGA-3′, comple-
mentary to nucleotides 753–774 of the BRSV 375 G gly-
coprotein, with a BamHI restriction site incorporated 
(underlined). The BRSV G cDNA was amplified using 
Taq polymerase (Invitrogen), with primers G2 and G1, 
5′-CAAAGGATCCTATGTCCAACCATACCCATCAT-
3′, corresponding to nucleotides 1–21 of BRSV G. BRSV 
G-specific primers were purchased from Sigma Genosys 
(Woodlands, TX). The reaction mixture was denatured 
at 94 °C for 1 min, annealed at 59 °C for 1 min, and ex-
tended at 72 °C for 2 min for a total of 30 cycles, followed 
by an additional extension of 7 min at 72 °C.
The BRSV G PCR product was gel purified (QIAEX II 
Gel Extraction Kit, QIAGEN, Chatsworth, CA) and sub-
cloned into pCR 2.1 vector using the TA Cloning Kit (In-
vitrogen). The BRSV G cDNA was excised from pCR2.1 
with SpeI and EcoRV and ligated using T4 DNA ligase into 
the mammalian expression vector, pcDNA 3.1/His (Invi-
trogen), digested with EcoRV and XbaI. This procedure 
placed the full-length BRSV G cDNA downstream of the 
T7 RNA polymerase and human cytomegalovirus imme-
diate-early promoter/enhancer and upstream of the bo-
vine growth hormone polyadenylation signal sequence. 
DNA sequencing (DNA Sequencing Facility, Iowa State 
University, Ames, IA) was performed following cloning 
to verify the orientation and reading frame of the insert.
2.3. Construction of plasmid DNA vectors encoding secreted 
and conserved BRSV G
To amplify secreted and conserved BRSV G, PCR was 
performed on the pcDNA 3.1/His construct encoding 
the 794 bp full-length BRSV G cDNA sequence using the 
parameters previously described. Primers G2 and SG1, 
5′-GGGCACAGGATCCGCAATGATAACC-3′, corre-
sponding to nucleotides 129–150, were used to amplify 
secreted BRSV G (657 bp). The 85 bp conserved region of 
BRSV G was amplified using primers CG2, 5′-ATGGATC-
CAGCAGAGTGATAAGCAAGC-3′, complementary to 
nucleotides 541–558 and CG1, 5′-CACAGGATCCGC-
GCAAACACTC-3′, corresponding to nucleotides 484–
504. Gel purified secreted and conserved BRSV G cDNA 
were inserted into pCR 2.1 vector, respectively, using 
3764 Br a d y,  to p l i f f ,  & Ke l l i n g i n Vaccine  22 (2004) 
the TA Cloning Kit. The secreted BRSV G region was ex-
cised from pCR2.1 with SpeI and EcoRV and ligated us-
ing T4 DNA ligase into pcDNA 3.1/His, digested with 
EcoRV and XbaI. Likewise, conserved BRSV G was ex-
cised from pCR 2.1 with SpeI and ApaI and ligated into 
pcDNA 3.1/His, digested with ApaI and XbaI, followed 
by DNA sequencing.
2.4. Expression of BRSV G constructs in mammalian cells
Expression of the recombinant BRSV G glycoproteins 
was evaluated in African green monkey kidney (COS-7) 
cells (American Type Culture Collection, Rockville, MD) 
following transfection using a vaccinia virus-T7 RNA 
polymerase expression system [29]. The T7-vaccinia vi-
rus was kindly provided by Dr. Bernard Moss, National 
Institutes of Health, Bethesda, MD. Following infection 
with T7-vaccinia virus, the COS-7 cells were transfected 
with plasmid DNA according to the manufacturer’s in-
structions using a cationic lipid-mediated method (Lipo-
fectamine 2000 Reagent, Invitrogen).
Twenty-four hours following the start of transfection, 
the COS-7 cells were fixed in 20% acetone (v/v) in phos-
phate buffered saline (PBS) and BRSV G detected using 
an immunoperoxidase staining protocol [30]. BRSV G 
protein was detected with the monoclonal antibody MAb 
57, specific for the central conserved cysteine-rich region 
of BRSV G [31] (kindly provided by Dr. Geraldine Taylor, 
Institute for Animal Health, Compton, UK), or polyclonal 
anti-BRSV serum as the primary antibody and biotinylated 
horse anti-mouse or goat anti-bovine IgG (H+L)(Vector 
Laboratories, Burlingame, CA), respectively, as the sec-
ondary antibody. Antibody binding was detected using 
streptavidin horseradish peroxidase conjugate (Zymed, 
San Francisco, CA) and 3-amino-9-ethyl-carbazole sub-
strate (Sigma, St. Louis, MO). Additionally, transfected 
cells were lysed using 0.5% NP-40 lysis buffer, then pro-
teins separated by discontinuous SDS-PAGE electropho-
resis. The separated proteins were transferred onto a ni-
trocellulose membrane and non-specific sites blocked in 
5% nonfat dry milk. The membrane was then incubated 
with the primary antibody, MAb 57 (1:1000), followed by 
alkaline phosphatase-labeled goat anti-mouse IgG (H+L) 
(KPL, Gaithersburg, MD) as the secondary antibody. An-
tibody binding was detected using 5-bromo-4-chloro-3-
indolyl-phosphate/nitroblue tetrazolium substrate (KPL, 
Gaithersburg, MD).
2.5. DNA inoculation of BALB/c mice
Plasmid DNA encoding the full-length, secreted and 
conserved BRSV G glycoprotein was purified using 
the plasmid Mega kit from QIAGEN according to the 
manufacturer’s instructions and resuspended in 0.89% 
NaCl. Four-week old, female, specific pathogen-free 
BALB/c mice, purchased from Charles River Laborato-
ries (Wilmington, MA), were housed in BL-2 rooms at 
the Animal Research Facility, University of Nebraska, 
Lincoln.
Mice were assigned to one of four treatment groups: 
(1) pcDNA 3.1/His/full-length BRSV G (DNA-G); 
(2) pcDNA 3.1/His/secreted BRSV G (DNA-SG); (3) 
pcDNA 3.1/His/conserved BRSV G (DNA-CG); or (4) 
pcDNA 3.1/His/Lac Z (DNA-Lac Z). DNA-Lac Z served 
as a negative control for the experimental design. Each 
treatment group was comprised of five mice. Mice were 
inoculated intramuscularly (IM), in the hind leg, with 
50 μg of plasmid DNA. The mice were given a booster 
inoculation at 4, 8, 12 and 17 weeks by the same route 
and with the same dose of plasmid DNA. Four weeks 
following the final inoculation, mice were anesthetized 
with 40 μg/g ketamine and 6 μg/g xylazine and bled by 
cardiac puncture. An equal amount of Alsever’s solution 
was added to the collected blood. The mice were then eu-
thanatized by CO2 inhalation.
2.6. Antibody response in mice following plasmid DNA 
inoculation
Plasma was analyzed for anti-BRSV G antibodies us-
ing an indirect enzyme-linked immunosorbent assay 
(ELISA) protocol described by Tripp et al. 1999 [32] with 
modifications. The antigen used for the ELISA consisted 
of BT cells infected with BRSV using an m.o.i. of 0.1 or 
non-infected cells. Four days following infection, the 
cells were fixed in 20% acetone in PBS (v/v). Two-fold 
dilutions of mouse plasma were prepared and added to 
the cells in 100 μl volumes. The plates were incubated at 
37 °C for 1 h, followed by addition of goat anti-mouse 
IgG (H+L) conjugated to alkaline phosphatase (1:1000) 
(KPL, Gaithersburg, MD) for an additional hour at 37 °C. 
The substrate, p-nitrophenyl phosphate, was then added 
and the optical density (OD) values were determined at 
410 nm using a microplate reader (MR 700, Dynatech 
Laboratories).
2.7. Detection of virus-neutralizing antibodies
For the detection of virus-neutralizing antibodies, two-
fold serial dilutions of heat-inactivated plasma (56 °C for 
30 min) were made and combined with BRSV (100–200 
TCID50/50 μl) for 1 h at 37 °C, with 5% CO2. The virus–
plasma mixtures were then tested for residual CPE in 
cultures of BT cells [33]. Monolayers were examined mi-
croscopically for viral CPE 4–7 days following infection 
and virus-neutralizing antibody titers were expressed as 
the highest plasma dilution inhibiting CPE of BRSV.
2.8. Statistical analysis
Results in the different treatment groups of mice were 
compared and analyzed statistically using a two-sam-
ple Student’s t-test. P-values of < 0.05 were considered 
to be statistically significant. Results were presented as 
mean±S.E.M.
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3. Results
3.1. Plasmid DNA vectors for in vitro and in vivo analysis
The three different plasmid vectors for DNA inoculation 
were constructed. Agarose gel electrophoresis verified 
inserts of the appropriate size following restriction endo-
nuclease digestion and DNA sequencing confirmed that 
the inserts were in the correct orientation, as well as in 
the proper reading frame (data not shown). The vectors 
encoded: (1) the full-length BRSV G protein; (2) a trun-
cated BRSV G protein which is secreted; or (3) a central, 
fully-conserved region of the BRSV G protein (Figure 1). 
Using a vaccinia virus/T7 expression system, transcrip-
tion was under the control of the vaccinia/T7 promoter, 
and the ampicillin-resistance gene, included in the vec-
tor, enabled selection in Escherichia coli.
3.2. COS-7 cells express the recombinant BRSV G 
glycoproteins
Expression was evaluated using an immunoperoxidase 
assay. Widespread, intracellular cytoplasmic staining 
was detectable in COS-7 cells transfected with plasmid 
DNA vectors encoding full-length, secreted, or conserved 
BRSV G (Figure 2). The level of intracellular cytoplas-
mic staining was equivalent in distribution and intensity 
among the three recombinants, and similar in intensity 
to BRSV-infected cells. As a negative control, COS-7 cells 
were transfected with the plasmid DNA backbone and 
no intracellular cytoplasmic staining was observed.
Based on Western blot analyses of lysates from COS-7 
cells transfected with plasmid DNA encoding the BRSV 
G proteins, the BRSV full-length and secreted G recom-
binants expressed proteins (Figure 3). Lysates collected 
Figure 1. Schematic diagram of the pcDNA3.1/His expression vector encoding the BRSV full-length, secreted, or conserved G gly-
coprotein. The pcDNA 3.1/His backbone was approximately 5.5 Kb in length. Transcription was under the control of the CMV 
immediate-early promoter, or T7 promoter when using a T7 vaccinia virus expression system. An ampicillin resistance gene was 
included for propagation of plasmids in E. coli under ampicillin selection. BamHI restriction sites were incorporated within the for-
ward and reverse BRSV G primers for verification of the insert.
Figure 2. Intracellular cytoplasmic staining using an immunoperoxidase assay in COS-7 cells transiently transfected with plasmid 
DNA encoding full-length, secreted (SG), or conserved (CG) BRSV G. (A) COS-7 cells transfected with the plasmid DNA back-
bone. (B) BRSV-infected COS-7 cells detected with MAb 57, specific for BRSV G. (C) COS-7 cells transfected with DNA-G and de-
tected with polyclonal anti-BRSV serum. COS-7 cells transfected with DNA-G (D), DNA-SG (E), and DNA-CG (F), and detected 
with MAb 57.
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from BRSV-infected COS-7 cells and from COS-7 cells 
transfected with the plasmid DNA backbone were used 
as positive and negative controls, respectively. The full-
length BRSV G recombinant resolved as several bands 
of similar intensity ranging in size from 70 to 90 kDa, 
equivalent in size to the band in the positive control lane. 
In contrast, the secreted BRSV G recombinant expressed 
primarily as a protein near 45 kDa, with a faint band re-
solving slightly lower than the full-length protein. Ex-
pression of the conserved BRSV G recombinant was not 
detectable by Western blot analysis (data not shown).
3.3. Anti-BRSV G IgG response following plasmid DNA 
inoculation
To evaluate the antibody response to the BRSV G recom-
binant proteins, plasma samples from mice inoculated 
with plasmid DNA encoding the BRSV G full-length and 
truncated proteins were used in an indirect ELISA and 
analyzed for antibodies using BRSV-infected and non-
infected BT cells as antigen. Specifically, the ratio of the 
OD410 nm values obtained from BRSV-infected cells to 
OD410 nm values obtained from non-infected cells were 
plotted at each dilution of plasma (Figure 4). Based on 
these results, BRSV G-specific IgG antibody titers were 
approximately 1:80 for DNA-G, DNA-SG, and DNA-
CG. Plasma from mice infected with live BRSV was 
used as a positive control for ELISA. The described ra-
tios for BRSV-infected mice were greater than the ratios 
for DNA-inoculated mice. As a negative control, plasma 
samples obtained from mice inoculated with DNA-Lac Z 
were analyzed by ELISA. There was not a detectable an-
tibody response in DNA-Lac Z inoculated mice, based 
on the described ratios, as they remained at a baseline 
level at each dilution.
3.4. DNA encoding the BRSV G full-length and truncated 
proteins did not induce virus-neutralizing antibodies
Following plasmid DNA inoculation of BALB/c mice, 
plasma was analyzed for neutralizing antibodies against 
BRSV. Inoculation with plasmid DNA encoding the 
BRSV G full-length and truncated proteins did not lead 
to a marked virus-neutralizing antibody response, as 
the mean VN titer was <4, based on inhibition of CPE in 
BRSV-infected BT cells (data not shown).
4. Discussion
In this study, plasmid DNA vectors encoding the full-
length, secreted and conserved regions of the BRSV G 
glycoprotein were constructed for DNA immunization 
to evaluate their expression in cell culture and potential 
to induce antibody responses in BALB/c mice. All three 
plasmid vectors were efficiently expressed in transfected 
COS-7 cells. To our knowledge, this is the first report of a 
Figure 3. COS-7 cells transfected with DNA-SG and DNA-G 
expressing the BRSV G glycoprotein. The lysates of transfected 
COS-7 cells were analyzed for expression of the BRSV G gly-
coprotein by Western blot analyses using a BRSV G-specific 
monoclonal antibody (MAb 57). Lysate collected from COS-7 
cells transfected with the plasmid DNA encoding a Lac Z gene 
(DNA-Lac Z) was used as a negative control. BRSV-infected 
COS-7 cell lysate was used a positive control.
Figure 4. Anti-BRSV G IgG antibody responses in BALB/c mice 
following inoculation with DNA-G (open circle), DNA-SG 
(closed triangle), DNA-CG (open square), DNA-Lac Z (open 
triangle), or with live BRSV (closed square). An indirect ELISA 
was used to evaluate the antibody response to the plasmid 
DNA encoding the BRSV G full-length and truncated proteins. 
Optical density (OD)410 nm values from plates using BRSV-in-
fected BT cells as antigen were compared against OD410 nm val-
ues of plates using non-infected cells as antigen, and the mean 
ratios plotted at each dilution ± S.E.M. (*P < 0.05 vs. DNA-Lac 
Z inoculated mice).
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study comparing expression and immunogenicity of the 
full-length, secreted, and conserved regions of the BRSV 
G glycoprotein using a plasmid DNA vaccine. DNA vac-
cination has been described using a number of infectious 
agents, such as HIV [34], and has been shown to elicit 
protection against a number of virulent pathogens, in-
cluding Hepatitis B virus [35]. We evaluated the G gly-
coprotein of BRSV in a plasmid DNA vaccine, as it is a 
major protective antigen that has also been linked to im-
mune-mediated enhanced disease. As a result, the avail-
ability of these DNA vaccines will permit studies of the 
immune response specific to the BRSV G glycoprotein, 
and may prove useful for studies aimed at gaining a bet-
ter understanding of the pathogenesis of BRSV respira-
tory disease.
Analysis of the recombinant proteins in transfected 
COS-7 cells by an immunoperoxidase assay demon-
strated that the expression of these constructs encod-
ing the full-length, truncated and conserved regions of 
BRSV G was comparable among the groups and similar 
to that of the wild-type protein. Additionally, expression 
of plasmid DNA encoding full-length or secreted BRSV 
G in transfected COS-7 cells was evaluated by Western 
blot analyses. The full-length BRSV G protein resolved 
as several bands of equivalent intensity between 70 and 
90 kDa, consistent with previous findings demonstrat-
ing that the G glycoprotein of BRSV migrates as a broad 
band near 80–90 kDa [36, 37]. The migration patterns ob-
served may be due to the accumulation of less-glycosyl-
ated forms of the G glycoprotein in the transfected cells, 
as less-glycosylated forms of G accumulate in substan-
tial quantity [36, 37]. The secreted BRSV G protein accu-
mulated mainly as an intense band near 45 kDa, with a 
faint band resolving slightly lower than the full-length 
protein. This pronounced band near 45 kDa is likely a 
BRSV G precursor, incompletely glycosylated, with only 
N-linked sugars [37]. The conserved region of the BRSV 
G glycoprotein was not detected by Western blot analy-
sis due to lesser sensitivity of this procedure compared 
to the immunoperoxidase procedure.
Production of anti-BRSV G IgG antibody titers of ap-
proximately 1:80 in mice following immunization with 
the three constructs, as determined by ELISA, were con-
sistent with previous findings following plasmid DNA 
immunization of mice encoding HRSV G, where HRSV-
specific IgG titers were ≥1:64 [30]. Similarly, others have 
demonstrated a detectable anti-HRSV G IgG response 
in BALB/c mice following plasmid DNA immunization 
[24–27]. The anti-BRSV G IgG titers (1:80) were similar 
among each of the three treatment groups (i.e. DNA-G, 
DNA-SG, and DNA-CG).
In summary, plasmid DNA constructs encoding the 
full-length, secreted, or conserved region of BRSV G 
were expressed equally in transfected COS-7 cells. Ad-
ditionally, following inoculation of BALB/c mice with 
plasmid DNA encoding the full-length, secreted, or con-
served BRSV G glycoprotein, a significant and compara-
ble anti-BRSV G IgG response was elicited with each of 
the three constructs. Future studies involving the immu-
nization of the natural host with plasmid DNA encod-
ing the full-length, secreted and conserved regions of the 
BRSV G glycoprotein will provide information regard-
ing protective immunity against challenge exposure.
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